SENSORION: management transactions · France · AMF

About SENSORION

Sensorion is a French clinical-stage biotechnology company focused on hearing disorders and, more broadly, on developing innovative therapies to restore, treat, and prevent hearing loss. Founded in 2009 and listed on Euronext in 2015, the company is headquartered in Montpellier, France, where most of its research, development, and corporate operations are based. It also maintains an international footprint through wholly owned subsidiaries in the United States, the United Kingdom, and Australia, supporting clinical development, regulatory work, and broader strategic execution. Sensorion’s business model is built around a highly specialized therapeutic niche at the intersection of biotechnology and ear, nose and throat medicine. The company’s pipeline is organized around two main platforms. First, it is developing SENS-401 (Arazasetron), an orally available small molecule designed to protect and preserve inner-ear tissue from damage. This asset has been evaluated in several indications, including sudden sensorineural hearing loss, preservation of residual hearing after cochlear implantation, and cisplatin-induced ototoxicity, with clinical milestones reported in 2024. Second, Sensorion is advancing gene therapy programs, notably SENS-501 (Audiogene), developed with Institut Pasteur for children carrying OTOF mutations, which cause severe to profound congenital hearing loss. The company has also discussed preparation work on SENS-601, a gene therapy candidate targeting GJB2, one of the most common genetic causes of early-onset deafness. From a market perspective, Sensorion remains a small-cap biotech with no commercial product yet, making its valuation largely dependent on clinical progress, regulatory de-risking, and financing capacity. Its competitive strengths lie in deep specialization, academic and industrial partnerships, and a pipeline addressing areas of major unmet medical need. Recent clinical updates, continued advancement of key programs, and the January 2026 capital increase that brought Sanofi into the shareholder base have all improved the company’s strategic visibility.